For successful gene therapy in hepatic enzyme deficiencies, it is essential to use promoters that can maintain strong transcriptional activity for the long term in the liver. Using Gunn rats, a model animal for Crigler-Najjar syndrome type I, the long-term transcriptional function of the CAG promoter (a combination of chicken P-actin promoter and cytomegalovirus immediate-early enhancer) was evaluated in the rat liver. We constructed a plasmid pCAGGHUGT, containing expression cassettes of human bilirubin UDP-glucuronosyltransferase (BUGT) and hygromycin phosphotransferase, under the control of the CAG promoter and murine phosphoglycerate kinase promoter, respectively. Conditionally immortalized Gunn rat hepatocytes (IGRH), which had been established using mutant SV40 large T antigen ( TS T), were transfected with pCAG GHUGT. A stably transfected clone IGRHUGT, expressing a high level of BUGT, was obtained after selec tion with hygromycin. At 33°C, the cells doubled in number in approximately 72 h; however, at 37°C, cell proliferation stopped, indicating that the characteristic of temperature-dependent proliferation was retained in this clone. Ten million cells were injected into the spleen of syngeneic Gunn rats five times at 10-day intervals. Serum bilirubin levels were reduced by 45-50% at 70 days after the first transplantation and remained so throughout the duration of the study (120 days). These results suggested that the CAG promoter was able to maintain strong transcriptional activity in rat liver for at least 120 days.
INTRODUCTION
Glucuronidation of bilirubin by hepatic bilirubin-uri dine diphosphate-glucuronosyltransferase (BUGT) is es sential for effective excretion of bilirubin from the liver.
Congenital deficiency of BUGT activity leads to
Crigler-Najjar syndrome type I in humans. This autoso mal recessive disorder is characterized by lifelong hy perbilirubinemia resulting in bilirubin encephalopathy at infancy or in adolescence (22) . Currently, liver trans plantation is the only definitive treatment for Crigler-Najjar syndrome type I. Homozygous Gunn rats having a similar metabolic defect are an authentic animal model for this syndrome (1, 23) . Gunn rats have been used ex tensively for the study of the pathophysiology of biliru bin metabolism (17, 21) , and for the research on liverdirected gene therapy, because therapeutic efficacy is easily evaluated by determination of serum bilirubin concentrations and excretion of bilirubin glucuronides in bile (6) (7) (8) . Conditionally immortalized Gunn rat hep atocytes (IGRH) (4) were established by infecting pri mary Gunn rat hepatocytes with a recombinant retrovi rus transferring the gene for a thermolabile mutant SV40 large T antigen ( TS T) (9) . At a permissive temperature (33°C), the transduced cells expressed the TS T antigen, which promoted cell proliferation. At 37-39°C, the cells stopped growing and exhibited differentiated function as hepatocytes (4) . Transplantation of genetically engi neered IGRH cells in Gunn rats indicated that these cells were engrafted efficiently in the hepatic bed after intras plenic injection (26) . The CAG promoter was con structed by the combination of chicken P-actin promoter and cytomegalovirus immediate-early enhancer (16) .
This promoter expresses with high efficiency transfected exogenous genes in various mammalian cell lines in vitro. The strong activity of the CAG promoter has been reported in rodent hepatocytes in vivo (12) . In this study, a recombinant adenoviral vector expressing an exoge nous gene under the control of the CAG promoter was administered intravenously into rats, resulting in a high level of transgene expression in the hepatocytes. Al though these studies demonstrated the strong transcrip tional activity of the CAG promoter in hepatocytes in vivo, the long-term efficacy of the CAG promoter could not be evaluated, because of the relatively short duration of gene expression by the adenoviral gene transfer sys tem. In the present study, we examined the long-term transcriptional activity of the CAG promoter in rat hepa tocytes in vivo by transplantation of Gunn rats with gene-transferred IGRH cells.
MATERIALS AND METHODS

Animals
Inbred Gunn rats and congeneic normal Wistar RHA rats were bred and maintained by T.O. at the National Children's Medical Research Center. All rats were maintained in accordance with the guidelines of the Ani mal Committee of the facility.
Plasmid Construction
The plasmid pCAGGS (16) was digested with ZscoRI, blunt-ended with Klenow fragment of E. coli DNA poly merase, and ligated with cDNA of human BUGT (25) . Then the plasmid was again digested with BamHl, and the expression cassette of hygromycin phosphotransfer ase gene was introduced under the control of phosphoglycerate kinase promoter (14) to generate the plasmid pCAGGHUGT ( Fig. 1 ).
Cloning of Immortalized Gunn Rat Hepatocytes Expressing Human BUGT
Conditionally immortalized Gunn rat hepatocytes (IGRH) (4) were transfected with pCAGGHUGT using lipofectamine plus (GIBCO BRL, Grand Island, NY) following the manufacturer's protocol. Forty-eight hours after the transfection, 30 pg/ml of hygromycin (Wako, Osaka, Japan) was added to the media, and continued the culture until each colony was clearly identified. Six teen colonies were picked out arbitrarily and further propagated.
Determination of BUGT Activity
Activity of bilirubin UGT was measured by the method described previously (13) . Briefly, labeled UDPglucuronic acid {(glucuronyl-[ l4 C(U)]) UDP; 10.55 GBq/mmol}(Dupont-NEN, Wilmington, DE) was incu bated with cell homogenates, and the reaction mixtures were subjected to TLC. The expression cassette of BUGT was generated by subcloning of BUGT cDNA at the EcoRl site of pCAGGS (16) . Then the plasmid was again digested with BamHl and an expression cassette for hygromycin phosphotransferase gene under the control of phosphoglycerate kinase promoter was also introduced. CAG: CAG promoter, UGT: cDNA of human BUGT, PAl: rabbit p-globin polyadenylation signal, PGK: murine phosphoglycerate kinase promoter, PA2: murine polya denylation signal of phosphoglycerate kinase gene.
CAG UGT
HPLC Analysis of Bilirubin Glucuronides
Bilirubin glucuronidation in a medium of IGRHUGT was analyzed by reverse phase HPLC using a Nova pack C18 column (Millipore-Waters, Milford, MA) based on the method described by Muraca and Blanckaert (15) with some modifications (20, 24) . Peaks were detected by absorbance at 436 nm, identified by retention time using authentic bilirubin standards, and quantified by in tegration of the areas under the curve.
Determination of Serum Bilirubin Levels
Serum bilirubin levels were measured using a Vision kit (Abbott, Abbott Park, IL) according to the manufac turer's protocol.
RESULTS
Establishment of Immortalized Gunn Rat Hepatocytes Overexpressing Human Bilirubin-UDP-Glucuronosyltransferase
The conditionally immortalized Gunn rat hepatocytes (IGRH) were transfected using cationic liposome with the plasmid pCAGGHUGT, which was carrying both expression cassettes of human bilirubin-UDP-glucuronosyltransferase (UBGT) and hygromycin phosphotrans ferase. After the selection with 30 pg/ml hygromycin for 14 days, 16 colonies were arbitrarily selected and expanded by culturing at a permissive temperature (33°C). Activities of BUGT were assayed with cell ho mogenates of each clone. The average BUGT activity of the six clones, which were selected arbitrarily, was 8.42 nmol/min/mg (0.10-27.23 nmol/min/mg). The highest specific BUGT activity corresponded to 150% of the ac tivity of normal rat liver homogenates. The clone "IGRHUGT," which showed the highest specific activ ity, was used for further analysis.
Temperature-Dependent Proliferation of IGRHUGT
To study the temperature-dependent proliferation of IGRHUGT, the cells were cultured at 33°C or 37°C, and cell counts were determined at 24-h intervals. At 33°C, the cells doubled in number in approximately 72 h (Fig.   2 ). On the other hand, when the cells were cultured at 37°C, their number did not increase significantly, sug gesting that this clone maintained temperature-depen dent proliferation characteristics similar to those of its original clone, "IGRH" (4) .
Bilirubin Glucuronidation In Vitro
The activity of bilirubin glucuronidation in IGRHUGT was analyzed by detecting bilirubin glucuronides with HPLC after adding 85.0 pmol/L of free bilirubin to the culture media of the cells. IGRHUGT showed 0.142 or 0.351 nmol/10 6 cells/h of bilirubin glucuronidation when the cells were cultured at 33°C or 37°C, respectively, indicating that the cells of IGRHUGT obtained the abil ity to carry out the complete glucuronidation process by the gene transfer of human BUGT (Fig. 3 ).
Amelioration of Hyperbilirubinemia in Gunn Rats After
Transplantation of IGRHUGT
In the process of seeding the cells into the hepatic bed, 1 x 10 7 IGRHUGT cells were injected into the spleen of syngeneic Gunn rats five times at 10-day inter vals. Serum bilirubin levels in Gunn rats were 5-8 mg/ dl before the transplantation. They decreased by 30% within a week, and the highest reduction (approximately 48%) was observed at 70 days after the first transplanta tion. At day 70, serum bilirubin levels slightly increased, but a 40-45% reduction was maintained throughout the duration of the study (120 days) ( Fig. 4) . These results suggested that the CAG promoter was able to maintain strong transcriptional activity in rat hepatocytes for at least 120 days in vivo. This study also demonstrated that the CAG promoter (16), a chicken P-actin promoter combined with cyto megalovirus immediate-early enhancer, maintained tran scriptional activity in Gunn rat liver at a high enough level to treat hyperbilirubinemia for at least 120 days (duration of the study). Although several promoters or promoter/enhancer combinations have been employed in animal experiments of liver-directed gene therapy (11, 18) , few experimental systems were designed to evaluate the long-term promoter activity in the liver. The transcriptional activities of several promoters or pro moter/enhancer combinations have been evaluated in the rat liver using a retroviral gene transfer system (5, 19) . Retroviral vectors expressing human a,-antitrypsin un der the control of the promoters of mouse albumin, mouse RNA polymerase II, or rat phosphoenolpyruvate carboxylkinase were evaluated in regenerating the rat liver. Although these results are useful in designing and constructing recombinant retroviruses for liver-directed gene therapy, they are not optimal for evaluating the . Effect of IGRHUGT transplantation on serum bili rubin levels. Ten million IGRHUGT or IGRH were injected into spleen of Gunn rats five times at 10-day intervals and serum bilirubin levels were determined every 10 days. In Gunn rats transplanted with IGRHUGT (O), serum bilirubin levels started to reduce within a week by 30%, and 40-45% reduc tion was maintained throughout the duration of the study (120 days). On the other hand, in Gunn rats receiving IGRH trans plants (•), no significant reduction of serum bilirubin levels was observed. Means and standard errors of the results ob tained on five rats in the therapeutic group and on three rats in the control group are shown.
DISCUSSION
promoter functions. As the long terminal repeat (LTR) regions of retroviruses have strong promoter activity, in teraction of the LTR promoter and an internal promoter cannot be neglected. In adenoviral systems, the activity of internal promoters can be determined on a short-term basis, but determination of long-term promoter function in the liver is not possible because of the limited dura tion of transgene expression by this episomal vector sys tem and the host immune response against the trans duced cells (2, 27) . The cell transplantation system described in this article could be very useful for testing long-term transcriptional activities of novel promoters or promoter/enhancer combinations in the liver, because it is free from the drawbacks of the retroviral or adenoviral systems.
Recently, the CAG promoter has been used widely in adenoviral constructs (10, 12) . An adeno-associated virus vector containing the CAG promoter has been reported as well (3) . As the CAG promoter exhibits long-term strong transcriptional activity in rodent liver, it should be appropriate to test novel vector systems in liver-di rected gene therapy using an expression cassette con taining this promoter.
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